The European Society of Anaesthesiology’ annual congress (Euroanaesthesia 2006) currently taking place in Madrid, Spain and the World Congress for Nurse Anesthetists starting later this week in Lausanne, Switzerland are the ideal platforms to continue to show the commitment of Organon to anesthesia and meet with the anesthesia professionals.

“Organon has a long history in the development and marketing of innovative products that support anesthesiologists and contribute to patient care. We recognize the achievements of anesthesiologists, the importance and complexity of the work they do and remain committed to continuing to meet their needs through development of innovative solutions that assist them in caring for their patients,” said Ron Riegman, Vice President, Global Franchise Lead Anesthesia.

In more than 40 years of anesthesia research and development together with anesthesiology professionals, Organon has introduced several innovative products into clinical practice, including Esmeron® the fast-onset muscle relaxant. First available in 1994, it has been used in over 125 million patients worldwide and remains one of the most widely used muscle relaxants in the global anesthesia market. Prior to Esmeron, Organon introduced Norcuron® in 1983, which at the time was considered a significant advance in neuromuscular blockade.

As well as providing innovative products for anesthesiologists, Organon continues to support several educational CME (Continuing Medical Education) activities via educational grants. Organon also supports AnesthesiaNow.com with an educational grant. This website is a valuable online professional information service for anesthesiology professionals around the world. The independent advisory board to this website announced this week that it had attracted more than 10,000 subscribers in less than one year since launch.

Riegman said that during both congresses the new Organon Anesthesia identity will be rolled out and that its main congress sponsorships illustrate the company’s ongoing commitment to this area as well as the study of sugammadex which is currently in phase III trials.

“This study product exemplifies the innovative approach that Organon takes and is continuing to take in the area of anesthesiology. The company has built up strong expertise in this area and is strongly committed to the introduction of future innovations,” added Herm Cukier, Executive Vice President of Global Marketing and Global Venture Teams. 

About Organon
Organon – with shared head offices in Roseland, NJ, USA and Oss, The Netherlands – creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: gynecology, fertility, neuroscience and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.